Distribution & Access For Publication Downloads News About Us Contact Us
Paper Titles
Crude Fucoidan Activity Extracted from Sargassum sp. as Mycotoxin (T-2) Binder
p.193
Study on Factors Affecting the Extraction of Ocimum basilicum Using Hydrodistillation Method
p.199
Antibacterial Activity of Traditional Medicine Scurrula atropurpurea (BL) DANS and their Endophytic Fungi
p.205
Antioxidant Activity of Sulfated Polysaccharide Extract from Green Seaweed (Caulerpa lentillifera) Makassar, Indonesia
p.214
Virtual Screening Based on Pharmacophore to Discover Host ER Alpha-Glucosidase II Inhibitor for Dengue Therapy
p.221
Utilization of Flavonoid Compounds as HER2 Tyrosine Kinase Inhibitor in Breast Cancer Using Fragment-Based Drug Design
p.230
Discovery of Novel α-Amylase Inhibitors as Type Two Diabetes Mellitus Therapy through Fragment-Based Drug Design
p.237
Synthesis N-Phenyl Pyrazoline from Dibenzalacetone and Heme Polymeration Inhibitory Activity (HPIA) Assay
p.245
Highly Efficient Synthesis of Oxindole Derivatives Via Catalytic Intramolecular C-H Insertion Reactions of Diazoamides
p.251

Virtual Screening Based on Pharmacophore to Discover Host ER Alpha-Glucosidase II Inhibitor for Dengue Therapy

Article Preview

Abstract:

Dengue is one of the crucial diseases in human-caused by dengue virus (DENV) infection. However, the development of DENV antiviral is often facing a problem because no effective drug to treat infection caused by all DENV serotypes. The inhibition of host protein involved in DENV life cycle can be a potential approach in dengue drug discovery, and also avoiding antiviral resistance. Endoplasmic Reticulum (ER) α-glucosidase II is one of the target host protein in DENV endoplasmic reticulum that plays an important role in the maturation process of DENV envelope glycoprotein. Natural products have been known as an essential source of a lead compound for drug discovery due to their therapeutic potency. In this research, pharmacophore-based virtual screening and molecular docking simulations were performed to find ligand that has potential to inhibit α-glucosidase II activity. About 67,609 natural products from InterBioScreen (IBS) database were used in the simulation as ligands with α-glucosidase II as the protein target. After subjected to Lipinski’s Rule of Five, druglikeness, nasty functions, and toxicity screening using DataWarrior software, 17,462 ligands were obtained. The pharmacophore features for molecular docking simulation was obtained from Protein-Ligand Interaction Fingerprint (PLIF) analysis using eight α-glucosidase II protein with different ligands. Based on virtual screening, rigid, and flexible docking simulations using Molecular Operating Environment (MOE) software, 32 ligands have lower Gibbs free binding energy (ΔGbinding) compared to the standards. Two best ligands, namely STOCK1N-85545 and STOCK1N-86400 which belong alkaloid derivatives, showed the exceptional ligand interaction and had the lowest ΔGbinding of-11.204 and-10.276 kcal/mol, respectively. The ligands were identified to have a binding interaction with amino acid Asp564 and Asp640 in α-glucosidase II catalytic site. STOCK1N-85545 and STOCK1N-86400 were also identified to have a good pharmacological properties after subjected to ADME-tox test using Toxtree, SwissADME, admetSAR, and pkCSM software.

You might also be interested in these eBooks
Symposium of Materials Science and Chemistry II View Preview

Info:

Periodical:

Key Engineering Materials (Volume 840)

Pages:

221-229

DOI:

https://doi.org/10.4028/www.scientific.net/KEM.840.221

Citation:

Cite this paper

Online since:

April 2020

Authors:

Elsafira Ariavianti, filia Stephanie, Usman Sumo Friend Tambunan*

Keywords:

Dengue Virus, Host ER Alpha-Glucosidase II, InterBioScreen Database, Natural Product, Pharmacophore

Export:

RIS, BibTeX

Price:

Permissions:

Request Permissions

* - Corresponding Author

References

[1] World Health Organization, Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. WHO Regional Publication SEARO, (2011).

Google Scholar

[2] H.A. Solanki, S.S. Shankar, H.A. Pandya, Dengue as a Druggable Disease: A Review, J. Fever. 1 (2017) 1-19.

Google Scholar

[3] M.G. Guzman, D.J. Gubler, A. Izquierdo, E. Martinez, S.B. Halstead, Dengue infection, Nat. Rev. Dis. Primers. 2 (2016) 1-25.

DOI: 10.1038/nrdp.2016.55

Google Scholar

[4] C.G. Noble, Y.L. Chen, H. Dong, F. Gu, S.P. Lim, W. Schul, Q.Y. Wang, P.Y. Shi, Strategies for development of dengue virus inhibitors, Antiviral Res. 85 (2010) 450-462.

DOI: 10.1016/j.antiviral.2009.12.011

Google Scholar

[5] B. de Chassey, L. Meyniel-Schicklin, J. Vonderscher, P. Andre, V. Lotteau, Virus-host interactomics: New insights and opportunities for antiviral drug discovery, Genome Med. 6 (2014) 1-14.

DOI: 10.1186/s13073-014-0115-1

Google Scholar

[6] A.T. Caputo, D.S. Alonzi, J.L. Kiappes, W.B. Struwe, A. Cross, S. Basu, B. Darlot, P. Roversi, Structural Insight into the Broad-Spectrum Antiviral Target Endoplasmic Reticulum Alpha Glucosidase II, Adv. Exp. Med. Biol. 1062 (2018) 265-276.

DOI: 10.1007/978-981-10-8727-1_19

Google Scholar

[7] J. Gu, Y. Gui, L. Chen, Y. Gu, H.-Z. Lu, X. Xu, Use of Natural Products as Chemical Library for Drug Discovery and Network Pharmacology, PLoS One. 8 (2013) e62839.

DOI: 10.1371/journal.pone.0062839

Google Scholar

[8] P. Chawla, A. Yadav, V. Chawla, Clinical implications and treatment of dengue, Asian Pac. J. Trop. Med. 7 (2014) 169-178.

Google Scholar

[9] R.R. Teixeira, W.L. Pereira, A.F.C. Da Silveira Oliveira, A.M. Da Silva, A.S. De Oliveira, M.L. Da Silva, C.C. Da Silva, S.O. De Paula, Natural products as source of potential dengue antivirals, Molecules. 19 (2014) 8151-8176.

DOI: 10.3390/molecules19068151

Google Scholar

[10] M. Laille, F. Gerald, C. Debitus, In vitro antiviral activity on dengue virus of marine natural products, Cell. Mol. Life Sci. 54 (1998) 167-170.

DOI: 10.1007/s000180050138

Google Scholar

[11] A.C. Koishi, P.R. Zanello, E.M. Bianco, J. Bordignon, C. Nunes Duarte dos Santos, Screening of dengue virus antiviral activity of marine seaweeds by an in situ enzyme-linked immunosorbent assay, PLoS One. 7 (2012) e51089.

DOI: 10.1371/journal.pone.0051089

Google Scholar

[12] M.C. Flechas, R.E. Ocazionez, E.E. Stashenko, Evaluation of in vitro Antiviral Activity of Essential Oil Compounds Against Dengue Virus, Pharmacogn. J. 10 (2018) 55-59.

DOI: 10.5530/pj.2018.1.11

Google Scholar

[13] S. Watanabe, A.P.S. Rathore, C. Sung, F. Lu, Y.M. Khoo, J. Connolly, J. Low, E.E. Ooi, H.S. Lee, S.G. Vasudevan, Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial, Antiviral Res. 96 (2012) 32-35.

DOI: 10.1016/j.antiviral.2012.07.008

Google Scholar

[14] S.T. Perry, M.D. Buck, E.M. Plummer, R.A. Penmasta, H. Batra, E.J. Stavale, K.L. Warfield, R.A. Dwek, T.D. Butters, D.S. Alonzi, S.M. Lada, K. King, B. Klose, U. Ramstedt, S. Shresta, An iminosugar with potent inhibition of dengue virus infection in vivo, Antiviral Res. 98 (2013) 35-43.

DOI: 10.1016/j.antiviral.2013.01.004

Google Scholar

[15] K.L. Warfield, E.M. Plummer, A.C. Sayce, D.S. Alonzi, W. Tang, B.E. Tyrrell, M.L. Hill, A.T. Caputo, S.S. Killingbeck, P.R. Beatty, E. Harris, R. Iwaki, K. Kinami, D. Ide, J.L. Kiappes, A. Kato, M.D. Buck, K. King, W. Eddy, M. Khaliq, A. Sampath, A.M. Treston, R.A. Dwek, S.G. Enterlein, J.L. Miller, N. Zitzmann, U. Ramstedt, S. Shresta, Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4, Antiviral Res. 129 (2016) 93-98.

DOI: 10.1016/j.antiviral.2016.03.001

Google Scholar

[16] J.L. Kiappes, A.C. Sayce, N. Zitzmann, R. Iwaki, D.S. Alonzi, J.L. Miller, M.L. Hill, A.T. Caputo, A. Kato, ToP-DNJ, a Selective Inhibitor of Endoplasmic Reticulum α-Glucosidase II Exhibiting Antiflaviviral Activity, ACS Chem. Biol. 13 (2018) 60-65.

DOI: 10.1021/acschembio.7b00870

Google Scholar

[17] T. Katsila, G.A. Spyroulias, G.P. Patrinos, M.T. Matsoukas, Computational approaches in target identification and drug discovery, Comput. Struct. Biotechnol. J. 14 (2016) 177-184.

DOI: 10.1016/j.csbj.2016.04.004

Google Scholar

[18] U.S.F. Tambunan, M.A.F. Nasution, Identification of novel Ebola virus (EBOV) VP24 inhibitor from Indonesian natural products through in silico drug design approach, AIP Conf. Proc. 1862 (2017) 1-9.

DOI: 10.1063/1.4991195

Google Scholar

[19] A.T. Caputo, D.S. Alonzi, L. Marti, I.-B. Reca, J.L. Kiappes, W.B. Struwe, A. Cross, S. Basu, E.D. Lowe, B. Darlot, A. Santino, P. Roversi, N. Zitzmann, Structures of mammalian ER α-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals, Proc. Natl. Acad. Sci. USA. 113 (2016) E4630- E4638.

DOI: 10.1073/pnas.1604463113

Google Scholar

[20] E.P. Toepak, M.A.F. Nasution, U.S.F. Tambunan, Fragment-based drug design of host endoplasmic reticulum α-glucosidase II inhibitors for dengue fever treatment using an integrated computational approach, AIP Conf. Proc. 2023 (2018) 020066-1-020066-6.

DOI: 10.1063/1.5064063

Google Scholar

[21] J. Peng, Y. Li, Y. Zhou, L. Zhang, X. Liu, Z. Zuo, Pharmacophore modeling, molecular docking and molecular dynamics studies on natural products database to discover novel skeleton as non-purine xanthine oxidase inhibitors, J. Recept. Signal Transduc. Res. 38 (2018) 246-255.

DOI: 10.1080/10799893.2018.1476544

Google Scholar

[22] D. Singh, Defining desirable natural product derived anticancer drug space: optimization of molecular physicochemical properties and ADMET attributes, ADMET and DMPK. 4 (2016) 98-113.

DOI: 10.5599/admet.4.2.291

Google Scholar

[23] S. Durdagi, J. Subbotina, J. Lees-Miller, J. Guo, H.J. Duff, S.Y. Noskov, Insights into the Molecular Mechanism of hERG1 Channel Activation and Blockade by Drugs, Curr. Med. Chem. 17 (2010) 3514-3532.

DOI: 10.2174/092986710792927886

Google Scholar

[24] H. van de Waterbeemd, E. Gifford, ADMET in silico modelling: towards prediction paradise?, Nat. Rev. Drug Discov. 2 (2003) 192-204.

DOI: 10.1038/nrd1032

Google Scholar

[25] A.P. Li, Screening for Human ADME/Tox Drug Properties in Drug Discovery, Drug Discov. Today. 6 (2001) 357-366.

DOI: 10.1016/s1359-6446(01)01712-3

Google Scholar

[26] A. Daina, O. Michielin, V. Zoete, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (2017) 42717.

DOI: 10.1038/srep42717

Google Scholar

Scientific.Net is a registered brand of Trans Tech Publications Ltd
© 2024 by Trans Tech Publications Ltd. All Rights Reserved